此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

2-阿替细胞复合物与D-核糖对纤维肌痛患者疼痛及临床病程的影响

2026年9月16日 更新者:Kubra Neslihan Kurt Oktay、Haydarpasa Numune Training and Research Hospital

2-阿替胞复合物与D-核糖对纤维肌痛综合征患者疼痛、症状及临床病程的影响

This multicenter, randomized, double-blind, placebo-controlled study will evaluate whether an oral supplement containing 2-Aticyto Complex and D-ribose (FibroThol), added to ongoing standard medical treatment, improves pain, symptoms, and clinical course in adults with fibromyalgia syndrome. Eligible participants are adults aged 18 to 65 years who have had fibromyalgia for at least 1 year and have been receiving pregabalin and/or duloxetine for at least 3 months. Participants will be randomly assigned to receive either FibroThol or placebo, administered as 15 mL three times daily for 4 weeks, while continuing their existing treatment. Follow-up assessments will be performed at baseline, week 2, and week 4 using patient-reported symptom and function measures. The study aims to determine whether this supportive supplement provides additional benefit compared with placebo in patients with persistent symptoms despite standard therapy.

研究概览

详细说明

Fibromyalgia syndrome is a chronic condition associated with widespread pain, fatigue, sleep disturbance, and reduced quality of life. Although standard pharmacologic treatments such as pregabalin and duloxetine are commonly used, symptom control may remain incomplete in many patients. This study was designed to investigate whether adding a supplement containing 2-Aticyto Complex and D-ribose to ongoing standard treatment can improve clinical outcomes in adults with fibromyalgia syndrome.

This is a multicenter, randomized, double-blind, placebo-controlled clinical study. Adults aged 18 to 65 years with fibromyalgia syndrome, diagnosed according to the ACR 2016 criteria, followed for at least 1 year, and receiving pregabalin and/or duloxetine treatment for at least 3 months will be eligible for participation. Major exclusion criteria include rheumatologic disease, renal failure, hepatic failure, cardiovascular disease, diabetes or hypoglycemia, neurologic disease, use of other supplements, allergy to study product ingredients, inability to complete study procedures, or refusal to participate.

After eligibility assessment and informed consent, participants will be randomly assigned to one of two study groups: placebo plus ongoing standard treatment or FibroThol plus ongoing standard treatment. The study treatment will be administered orally at a dose of 15 mL three times daily for 4 weeks. Study visits and assessments will be performed at baseline, week 2, and week 4.

Outcome measures will include pain intensity, neuropathic pain, fibromyalgia-related functional status, fatigue, sleep quality, anxiety, and depression, assessed using validated clinical scales. Safety will be evaluated through adverse event monitoring during the study period.

A total of 200 participants will be enrolled, with 100 participants assigned to the FibroThol group and 100 participants assigned to the placebo group. The primary objective is to determine whether the addition of 2-Aticyto Complex and D-ribose to standard treatment provides additional benefit in reducing pain and improving symptoms and overall clinical course in patients with fibromyalgia syndrome.

研究类型

介入性

注册 (估计的)

200

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Istanbul、土耳其(türkiye)、34480
        • University of Health Sciences, Basaksehir Cam and Sakura City Hospital, Department of Physical Medicine and Rehabilitation
        • 接触:
      • Istanbul、土耳其(türkiye)、34668
        • University of Health Sciences, Sultan Abdulhamid Han Training and Research Hospital, Department of Physical Medicine and Rehabilitation
        • 接触:
        • 副研究员:
          • Emre Ata, MD
      • Istanbul、土耳其(türkiye)、34732
        • Erenkoy Physical Therapy and Rehabilitation Hospital, Department of Physical Medicine and Rehabilitation
        • 接触:
      • Istanbul、土耳其(türkiye)、34752
        • University of Health Sciences, Fatih Sultan Mehmet Training and Research Hospital, Department of Physical Medicine and Rehabilitation
        • 接触:
    • Istanbul
      • Istanbul、Istanbul、土耳其(türkiye)、34662
        • University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Department of Physical Medicine and Rehabilitation
        • 接触:
        • 副研究员:
          • Arzu Erbilici, MD
        • 副研究员:
          • Duygu Geler Kulcu, MD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Adults aged 18 to 65 years
  • Diagnosis of fibromyalgia syndrome according to the 2016 ACR criteria
  • Followed in a physical medicine and rehabilitation outpatient clinic for at least 1 year
  • Receiving pregabalin and/or duloxetine treatment for at least 3 months
  • Able to live independently in the community
  • Literate and able to record symptoms and responses
  • No cognitive dysfunction that would interfere with answering study questions
  • Able and willing to provide informed consent

Exclusion Criteria:

  • Rheumatologic disease
  • Renal failure
  • Hepatic failure
  • Cardiovascular disease
  • Hypoglycemia or diabetes mellitus
  • Any neurologic disease (such as stroke, spinal cord injury, multiple sclerosis, or Parkinson's disease)
  • Known allergy or hypersensitivity to any active or excipient component of the study syrup
  • Use of any other dietary supplement or nutritional support product during the study period
  • Pregnancy or lactation
  • Active malignancy
  • Active infection
  • Severe psychiatric disease that may interfere with study participation or assessment
  • Refusal to participate or inability to provide informed consent

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:Placebo Plus Standard Treatment

Participants will receive matching placebo orally at 15 mL three times daily for 4 weeks, in addition to their ongoing standard medical treatment with pregabalin and/or duloxetine.

A matching oral placebo syrup without active study ingredients. In this study, participants will receive 15 mL orally three times daily for 4 weeks in addition to ongoing standard treatment with pregabalin and/or duloxetine. The placebo contains deionized water, glycerol, sodium alginate, xanthan gum, steviol glycosides, raspberry flavor, pineapple flavor, strawberry flavor, and mint flavor.

实验性的:FibroThol Plus Standard Treatment

Participants will receive FibroThol, an oral supplement containing 2-Aticyto Complex and D-ribose, at 15 mL three times daily for 4 weeks, in addition to their ongoing standard medical treatment with pregabalin and/or duloxetine.

An oral dietary supplement containing 2-Aticyto Complex and D-ribose (marketed as FibroThol). In this study, participants will receive 15 mL orally three times daily for 4 weeks in addition to ongoing standard treatment with pregabalin and/or duloxetine.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in Pain Intensity Measured by Numeric Rating Scale (NRS)
大体时间:Baseline, Week 2, and Week 4

Pain intensity will be assessed using the Numeric Rating Scale (NRS), an 11-point scale ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst pain imaginable. Higher scores indicate greater pain intensity. Change from baseline will be compared between groups.

Baseline, Week 2, and Week 4

次要结果测量

结果测量
措施说明
大体时间
Change in Neuropathic Pain Measured by DN4
大体时间:Baseline, Week 2, and Week 4

Neuropathic pain symptoms will be assessed using the Douleur Neuropathique 4 (DN4) questionnaire, with a total score range of 0 to 10. Higher scores indicate more neuropathic pain features, and a score of 4 or more suggests neuropathic pain. Change from baseline will be compared between groups.

Baseline, Week 2, and Week 4
Change in Fibromyalgia Impact Questionnaire Score
大体时间:Baseline, Week 2, and Week 4

Participation limitations will be assessed using the Fibromyalgia Participation Questionnaire, with transformed scale values ranging from 0 to 100. Higher scores indicate better participation and social functioning, so an increase from baseline reflects improvement.

Baseline, Week 2, and Week 4
Change in Fibromyalgia Participation Questionnaire Score
大体时间:Baseline, Week 2, and Week 4

Fatigue severity will be assessed using the Fatigue Severity Scale, a 9-item scale with a total score range of 9 to 63. Higher scores indicate greater fatigue severity. Change from baseline will be compared between groups.

Baseline, Week 2, and Week 4
Change in Fatigue Severity Scale (FSS) Score
大体时间:Baseline, Week 2, and Week 4

Participation limitations will be assessed using the Fibromyalgia Participation Questionnaire, with transformed scale values ranging from 0 to 100. Higher scores indicate better participation and social functioning, so an increase from baseline reflects improvement.

Baseline, Week 2, and Week 4
Change in Pittsburgh Sleep Quality Index (PSQI) Score
大体时间:Baseline, Week 2, and Week 4

Sleep quality will be assessed using the Pittsburgh Sleep Quality Index, with a global score range of 0 to 21. Higher scores indicate poorer sleep quality. Change from baseline will be compared between groups.

Baseline, Week 2, and Week 4
Change in Beck Depression Inventory Score
大体时间:Baseline, Week 2, and Week 4

Depressive symptoms will be assessed using the Beck Depression Inventory, a 21-item scale with a total score range of 0 to 63. Higher scores indicate more severe depressive symptoms. Change from baseline will be compared between groups.

Baseline, Week 2, and Week 4
Change in Beck Anxiety Inventory Score
大体时间:Baseline, Week 2, and Week 4

Anxiety symptoms will be assessed using the Beck Anxiety Inventory, a 21-item scale with a total score range of 0 to 63. Higher scores indicate more severe anxiety symptoms. Change from baseline will be compared between groups.

Baseline, Week 2, and Week 4

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Kubra Neslihan Kurt Oktay, MD、University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Department of Physical Medicine and Rehabilitation
  • 学习椅:Kubra Nesihan Kurt Oktay, MD、University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Department of Physical Medicine and Rehabilitation

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年10月4日

初级完成 (估计的)

2027年5月4日

研究完成 (估计的)

2027年5月4日

研究注册日期

首次提交

2026年3月23日

首先提交符合 QC 标准的

2026年3月23日

首次发布 (实际的)

2026年3月27日

研究记录更新

最后更新发布 (实际的)

2026年9月21日

上次提交的符合 QC 标准的更新

2026年9月16日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual participant data will not be shared. Aggregate results will be reported in publications and trial registry updates.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅